- Home
- RVTY vs BMRN Comparison
RVTY vs BMRN Comparison
Compare RVTY & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RVTY | BMRN |
|---|---|---|
| Founded | 1937 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.0B | 12.3B |
| IPO Year | 1994 | 1999 |
Fundamental Metrics
Financial Performance| Metric | RVTY | BMRN |
|---|---|---|
| Price | $158.18 | $56.00 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 18 | 28 |
| Target Price | ★ $147.53 | $91.59 |
| AVG Volume (30 Days) | 1.5M | ★ 2.2M |
| Earning Date | 11-03-2026 | 11-03-2026 |
| Dividend Yield | ★ 0.18% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.82 | 0.77 |
| Revenue | ★ $3,311,822,000.00 | $1,313,646,000.00 |
| Revenue This Year | N/A | $21.42 |
| Revenue Next Year | $5.44 | $14.51 |
| P/E Ratio | $191.17 | ★ $73.47 |
| Revenue Growth | N/A | ★ 17.62 |
| 52 Week Low | $81.22 | $49.26 |
| 52 Week High | $166.25 | $70.98 |
Technical Indicators
Market Signals| Indicator | RVTY | BMRN |
|---|---|---|
| Relative Strength Index (RSI) | 65.19 | 42.02 |
| Support Level | $146.70 | $53.89 |
| Resistance Level | $166.25 | $57.88 |
| Average True Range (ATR) | 6.24 | 1.60 |
| MACD | -0.54 | 0.33 |
| Stochastic Oscillator | 59.85 | 51.58 |
Price Performance
Historical ComparisonAbout RVTY Revvity Inc.
Revvity is a global life sciences and diagnostics company formed in 2023 following the rebranding of PerkinElmer. The company operates in two segments: life sciences, which provides reagents and instruments for biopharma and academic research, and signals software, and diagnostics, which offers tools in immunodiagnostics and newborn and reproductive health. Revvity's products and services are sold worldwide, with major markets in the US, Europe, and China.
About BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.